| 1 |
34715143 | Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells. | 2021 Dec 15 |
1 |
| 2 |
30980733 | Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. | 2019 Aug |
4 |
| 3 |
31152080 | Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. | 2019 Sep |
2 |
| 4 |
31345267 | A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. | 2019 Jul 25 |
1 |
| 5 |
29393180 | Role of Radiosensitizers in Radiation Treatment of Gliomas. | 2018 |
1 |
| 6 |
29925934 | Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. | 2018 Jul |
1 |
| 7 |
28933580 | The role of Cediranib in ovarian cancer. | 2017 Oct |
1 |
| 8 |
29270434 | High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform. | 2017 |
2 |
| 9 |
26626460 | Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer. | 2016 Jan 12 |
2 |
| 10 |
26753963 | Cediranib in ovarian cancer: state of the art and future perspectives. | 2016 Mar |
1 |
| 11 |
26802156 | A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). | 2016 May |
1 |
| 12 |
26841902 | A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. | 2016 Apr |
1 |
| 13 |
25684635 | Effects of receptor tyrosine kinase inhibitors on VEGF165 a- and VEGF165 b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2. | 2015 Jun |
1 |
| 14 |
26044202 | The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model. | 2015 Aug |
1 |
| 15 |
26179201 | Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. | 2015 Aug |
1 |
| 16 |
26186911 | A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. | 2015 Sep |
2 |
| 17 |
26188774 | A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. | 2015 Sep |
2 |
| 18 |
26415995 | Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. | 2015 Nov |
1 |
| 19 |
24309981 | Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. | 2014 Jan |
2 |
| 20 |
24752867 | Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. | 2014 Jul 15 |
3 |
| 21 |
23197081 | Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. | 2013 Feb |
5 |
| 22 |
23299530 | Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. | 2013 Feb 19 |
3 |
| 23 |
23362324 | Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. | 2013 Mar 15 |
1 |
| 24 |
23651727 | Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. | 2013 Apr |
1 |
| 25 |
23801303 | Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. | 2013 Oct |
2 |
| 26 |
24190997 | Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. | 2013 Nov 19 |
1 |
| 27 |
21422991 | Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. | 2012 Aug |
1 |
| 28 |
21538824 | Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. | 2012 Apr |
4 |
| 29 |
21611734 | Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. | 2012 Aug |
2 |
| 30 |
21828378 | Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. | 2012 Apr |
2 |
| 31 |
21853311 | Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. | 2012 Feb |
1 |
| 32 |
21989836 | Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. | 2012 Oct |
2 |
| 33 |
22127927 | Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. | 2012 Jan 15 |
1 |
| 34 |
22263801 | Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer. | 2012 Oct 1 |
1 |
| 35 |
22285180 | Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. | 2012 Mar |
3 |
| 36 |
22405734 | Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. | 2012 Oct |
1 |
| 37 |
22644562 | Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies. | 2012 Dec |
1 |
| 38 |
22830398 | Cediranib: a VEGF receptor tyrosine kinase inhibitor. | 2012 Jul |
2 |
| 39 |
22831987 | Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. | 2012 Oct |
1 |
| 40 |
22965965 | Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). | 2012 Oct 10 |
3 |
| 41 |
23013619 | Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. | 2012 Sep |
1 |
| 42 |
20607586 | Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. | 2011 Dec |
3 |
| 43 |
21120480 | A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. | 2011 Sep |
2 |
| 44 |
21199795 | Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. | 2011 Jan 1 |
2 |
| 45 |
21878941 | Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. | 2011 Sep 27 |
3 |
| 46 |
21964533 | Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. | 2011 Nov |
1 |
| 47 |
19674789 | An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. | 2010 Feb |
1 |
| 48 |
20056761 | Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. | 2010 Mar |
1 |
| 49 |
20184547 | Recent advances and future directions in the management of metastatic renal cell carcinoma. | 2010 Mar |
2 |
| 50 |
20409669 | Characterisation and identification of the human N+-glucuronide metabolite of cediranib. | 2010 Nov 2 |
3 |